Our Partners

At Aspira Women’s Health, we drive innovation through collaboration with top healthcare organizations, researchers, and health plans. Our partnerships aim to advance women’s health with hope of enabling earlier detection and better outcomes for women with ovarian cancer and other gynecologic diseases.

Our Commitment to Partnership

We collaborate with our partners to:

Deliver essential non-invasive women’s health risk assessment tests that aim to improve outcomes for women

Drive awareness of women's health issues through advocacy and awareness, ensuring accessibility and affordability of essential tests

Accelerate research and clinical studies for women’s health, including ovarian cancer risk assessment

AdobeStock_715418937_Preview

Our Valued Partners

Lab Providers

We work closely with laboratories of all sizes to help bring our FDA-cleared products into your commercial, health system or physician-owned laboratory through Aspira Synergy, our technology transfer platform.

Research Collaborators

By collaborating with medical providers and institutions to help develop and study diagnostic solutions, we are fostering breakthroughs in women’s health.

Market Access

Our partnerships with health plans enable broader access to personalized risk assessment testing by integrating our solutions into medical policy and streamlining the approval process.

Together, Advancing Women's Health

At Aspira Women’s Health, we are always seeking new partnerships that align our shared mission to improve health outcomes for women with ovarian cancer and other gynecologic diseases. Whether you are in healthcare, research, advocacy, or business, we invite you to join us in our quest to shape the future of women's health.

Contact Us

PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.

OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.

*In cases of an intermediate Ova1® result, the FDA-cleared Overa® reflex is performed to increase specificity